دورية أكاديمية
Decitabine enhances targeting of AML cells by CD34 + progenitor-derived NK cells in NOD/SCID/IL2Rg null mice.
| العنوان: | Decitabine enhances targeting of AML cells by CD34 + progenitor-derived NK cells in NOD/SCID/IL2Rg null mice. |
|---|---|
| المؤلفون: | Cany J; Department of Laboratory Medicine, Laboratory of Hematology., Roeven MWH; Department of Laboratory Medicine, Laboratory of Hematology.; Department of Hematology, and., Hoogstad-van Evert JS; Department of Laboratory Medicine, Laboratory of Hematology.; Department of Gynecology, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands; and., Hobo W; Department of Laboratory Medicine, Laboratory of Hematology., Maas F; Department of Laboratory Medicine, Laboratory of Hematology., Franco Fernandez R; Department of Laboratory Medicine, Laboratory of Hematology., Blijlevens NMA; Department of Hematology, and., van der Velden WJ; Department of Hematology, and., Huls G; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands., Jansen JH; Department of Laboratory Medicine, Laboratory of Hematology., Schaap NPM; Department of Hematology, and., Dolstra H; Department of Laboratory Medicine, Laboratory of Hematology. |
| المصدر: | Blood [Blood] 2018 Jan 11; Vol. 131 (2), pp. 202-214. Date of Electronic Publication: 2017 Nov 14. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : [New York] : Elsevier Original Publication: New York, Grune & Stratton [etc.] |
| مواضيع طبية MeSH: | Antimetabolites, Antineoplastic/*therapeutic use , Azacitidine/*therapeutic use , Decitabine/*therapeutic use , Immunotherapy, Adoptive/*methods , Killer Cells, Natural/*transplantation , Leukemia, Myeloid, Acute/*therapy, Animals ; Antigens, CD34/analysis ; Cells, Cultured ; Gene Deletion ; Humans ; Interleukin Receptor Common gamma Subunit/genetics ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Mice, Inbred NOD ; Mice, SCID |
| مستخلص: | Combining natural killer (NK) cell adoptive transfer with hypomethylating agents (HMAs) is an attractive therapeutic approach for patients with acute myeloid leukemia (AML). However, data regarding the impact of HMAs on NK cell functionality are mostly derived from in vitro studies with high nonclinical relevant drug concentrations. In the present study, we report a comparative study of azacitidine (AZA) and decitabine (DAC) in combination with allogeneic NK cells generated from CD34 + hematopoietic stem and progenitor cells (HSPC-NK cells) in in vitro and in vivo AML models. In vitro, low-dose HMAs did not impair viability of HSPC-NK cells. Furthermore, low-dose DAC preserved HSPC-NK killing, proliferation, and interferon gamma production capacity, whereas AZA diminished their proliferation and reactivity. Importantly, we showed HMAs and HSPC-NK cells could potently work together to target AML cell lines and patient AML blasts. In vivo, both agents exerted a significant delay in AML progression in NOD/SCID/IL2Rg null mice, but the persistence of adoptively transferred HSPC-NK cells was not affected. Infused NK cells showed sustained expression of most activating receptors, upregulated NKp44 expression, and remarkable killer cell immunoglobulin-like receptor acquisition. Most importantly, only DAC potentiated HSPC-NK cell anti-leukemic activity in vivo. Besides upregulation of NKG2D- and DNAM-1-activating ligands on AML cells, DAC enhanced messenger RNA expression of inflammatory cytokines, perforin, and TRAIL by HSPC-NK cells. In addition, treatment resulted in increased numbers of HSPC-NK cells in the bone marrow compartment, suggesting that DAC could positively modulate NK cell activity, trafficking, and tumor targeting. These data provide a rationale to explore combination therapy of adoptive HSPC-NK cells and DAC in patients with AML. (© 2018 by The American Society of Hematology.) |
| References: | Front Immunol. 2015 Feb 04;6:29. (PMID: 25699047) Stem Cells Dev. 2015 Dec 15;24(24):2886-98. (PMID: 26414401) Cancer Sci. 2011 Sep;102(9):1680-6. (PMID: 21624006) Nat Rev Cancer. 2017 May;17 (5):286-301. (PMID: 28338065) Genes Immun. 2015 Jan-Feb;16(1):71-82. (PMID: 25393931) Cancer Immunol Res. 2016 Jan;4(1):49-60. (PMID: 26511282) Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. (PMID: 20368434) Cytotherapy. 2015 Jun;17 (6):739-748. (PMID: 25795272) Oncoimmunology. 2017 May 11;6(8):e1320630. (PMID: 28919991) J Clin Med. 2014 Dec 25;4(1):1-17. (PMID: 26237015) Cancer Immunol Res. 2015 Sep;3(9):1030-41. (PMID: 26056145) Mol Immunol. 2009 Jun;46(10):2064-70. (PMID: 19394699) Am J Transl Res. 2015 Oct 15;7(10):1896-907. (PMID: 26692933) PLoS One. 2011;6(6):e20740. (PMID: 21698239) N Engl J Med. 2016 Feb 4;374(5):422-33. (PMID: 26789727) FASEB J. 2008 Mar;22(3):659-61. (PMID: 17942826) Biol Blood Marrow Transplant. 2016 Jun;22(6):1000-1008. (PMID: 26860635) Clin Cancer Res. 2016 Feb 1;22(3):596-608. (PMID: 26423796) Cell Commun Signal. 2017 Mar 31;15(1):13. (PMID: 28359286) Nat Immunol. 2014 May;15(5):431-8. (PMID: 24658051) J Clin Oncol. 2016 Feb 1;34(4):329-36. (PMID: 26668349) Clin Cancer Res. 2017 Aug 1;23 (15):4107-4118. (PMID: 28280089) Cytotherapy. 2008;10(6):625-32. (PMID: 18836917) Blood. 2005 Apr 15;105(8):3051-7. (PMID: 15632206) PLoS One. 2013 Jun 05;8(6):e64384. (PMID: 23755121) Blood. 2011 Sep 22;118(12):3273-9. (PMID: 21791425) Cytotherapy. 2015 Nov;17(11):1594-603. (PMID: 26341478) Leuk Lymphoma. 2013 Sep;54(9):2003-7. (PMID: 23270581) Cancer Immunol Immunother. 2010 Dec;59(12):1781-9. (PMID: 20703455) Rapid Commun Mass Spectrom. 2006;20(7):1117-26. (PMID: 16523529) Cancer Immunol Immunother. 2012 Sep;61(9):1441-50. (PMID: 22310929) Cancer Cell. 2015 Dec 14;28(6):690-714. (PMID: 26678337) Oncotarget. 2017 May 9;8(19):31959-31976. (PMID: 28404876) J Immunother. 2015 Jan;38(1):24-36. (PMID: 25415285) Cancer Discov. 2016 Apr;6(4):446-59. (PMID: 26787820) Int J Cancer. 2011 Jun 15;128(12):2911-22. (PMID: 20960460) Oncoimmunology. 2015 Apr 1;4(7):e1017701. (PMID: 26140247) J Immunol. 2004 Apr 1;172(7):3994-8. (PMID: 15034010) Stem Cells Dev. 2014 May 1;23(9):955-67. (PMID: 24325394) Blood Cancer J. 2014 Mar 28;4:e197. (PMID: 24681961) Leuk Res. 2007 Oct;31(10):1393-402. (PMID: 17391757) Mol Immunol. 2013 Jul;54(3-4):296-301. (PMID: 23328088) Cancer Sci. 2012 Oct;103(10):1839-47. (PMID: 22816487) |
| المشرفين على المادة: | 0 (Antigens, CD34) 0 (Antimetabolites, Antineoplastic) 0 (Il2rg protein, mouse) 0 (Interleukin Receptor Common gamma Subunit) 776B62CQ27 (Decitabine) M801H13NRU (Azacitidine) |
| تواريخ الأحداث: | Date Created: 20171116 Date Completed: 20190507 Latest Revision: 20210202 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC5757681 |
| DOI: | 10.1182/blood-2017-06-790204 |
| PMID: | 29138222 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1528-0020 |
|---|---|
| DOI: | 10.1182/blood-2017-06-790204 |